| A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods PW Serruys, JA Ormiston, Y Onuma, E Regar, N Gonzalo, ... The Lancet 373 (9667), 897-910, 2009 | 992 | 2009 |
| Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients … V Farooq, D Van Klaveren, EW Steyerberg, E Meliga, Y Vergouwe, ... The Lancet 381 (9867), 639-650, 2013 | 892 | 2013 |
| A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial JA Ormiston, PW Serruys, E Regar, D Dudek, L Thuesen, MWI Webster, ... The Lancet 371 (9616), 899-907, 2008 | 891 | 2008 |
| Assessment of the SYNTAX score in the Syntax study PW Serruys, Y Onuma, S Garg, G Sarno, M van den Brand, AP Kappetein, ... EuroIntervention 5 (1), 50-56, 2009 | 756 | 2009 |
| Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy … P Vranckx, M Valgimigli, P Jüni, C Hamm, PG Steg, D Heg, GA van Es, ... The Lancet 392 (10151), 940-949, 2018 | 689 | 2018 |
| Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document HM Garcia-Garcia, EP McFadden, A Farb, R Mehran, GW Stone, ... Circulation 137 (24), 2635-2650, 2018 | 682 | 2018 |
| Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous … L Räber, GS Mintz, KC Koskinas, TW Johnson, NR Holm, Y Onuma, ... European heart journal 39 (35), 3281-3300, 2018 | 681 | 2018 |
| A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II … PW Serruys, B Chevalier, D Dudek, A Cequier, D Carrié, A Iniguez, ... The Lancet 385 (9962), 43-54, 2015 | 670 | 2015 |
| Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year … PW Serruys, B Chevalier, Y Sotomi, A Cequier, D Carrié, JJ Piek, ... The Lancet 388 (10059), 2479-2491, 2016 | 590 | 2016 |
| Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging … PW Serruys, Y Onuma, D Dudek, PC Smits, J Koolen, B Chevalier, ... Journal of the American College of Cardiology 58 (15), 1578-1588, 2011 | 472 | 2011 |
| Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study L Räber, M Magro, GG Stefanini, B Kalesan, RT van Domburg, Y Onuma, ... Circulation 125 (9), 1110-1121, 2012 | 437 | 2012 |
| Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and … PW Serruys, Y Onuma, JA Ormiston, B de Bruyne, E Regar, D Dudek, ... Circulation 122 (22), 2301-2312, 2010 | 434 | 2010 |
| Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after percutaneous replacement of the aortic valve N Piazza, Y Onuma, E Jesserun, PP Kint, AM Maugenest, RH Anderson, ... JACC: Cardiovascular interventions 1 (3), 310-316, 2008 | 434 | 2008 |
| Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study C Gao, Y Cai, K Zhang, L Zhou, Y Zhang, X Zhang, Q Li, W Li, S Yang, ... European heart journal 41 (22), 2058-2066, 2020 | 432 | 2020 |
| From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? PW Serruys, HM Garcia-Garcia, Y Onuma European heart journal 33 (1), 16-25, 2012 | 386 | 2012 |
| Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine … Y Onuma, PW Serruys, LEL Perkins, T Okamura, N Gonzalo, ... Circulation 122 (22), 2288-2300, 2010 | 361 | 2010 |
| A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan T Kimura, K Kozuma, K Tanabe, S Nakamura, M Yamane, T Muramatsu, ... European heart journal 36 (47), 3332-3342, 2015 | 322 | 2015 |
| Dual antiplatelet therapy after PCI in patients at high bleeding risk M Valgimigli, E Frigoli, D Heg, J Tijssen, P Jüni, P Vranckx, Y Ozaki, ... New England Journal of Medicine 385 (18), 1643-1655, 2021 | 314 | 2021 |
| Long-Term (>10 Years) Clinical Outcomes of First-in-Human Biodegradable Poly-l-Lactic Acid Coronary Stents: Igaki-Tamai Stents S Nishio, K Kosuga, K Igaki, M Okada, E Kyo, T Tsuji, E Takeuchi, ... Circulation 125 (19), 2343-2353, 2012 | 314 | 2012 |
| 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo … PW Serruys, Y Onuma, S Garg, P Vranckx, B De Bruyne, MC Morice, ... Journal of the American College of Cardiology 55 (11), 1093-1101, 2010 | 308 | 2010 |
